Dalmia Bharat joins Covid-19 fight, donates Rs 25 cr to PM Fund
New Delhi, March 31 Business conglomerate Dalmia Bharat Group has committed Rs 25 crore to the PM-Cares Fund as part of its endeavour to assist the government's efforts against COVID 19.
"We are doing our duty by making a small contribution to the PMCARES and will do everything to support our Prime Minister and Chief Ministers in their efforts to fight the coronavirus," said Puneet Dalmia, Managing Director of the Dalmia Bharat Group.
Ration, grocery and accommodation were being provided to all contractual labourers stranded due to the nationwide lockdown, he said.
Apart from this, it is providing over 100 food packets twice a day to the local police and the municipalities to be distributed among the needy and homeless near its plants.
Dalmia Bharat Group has also committed playgrounds, guest houses and technical centres at its plants to the local authorities for use as facilities to house Covid-19 cases.
The canteens of Dalmia Bharat factories are being used to prepare food for local distribution.
To ensure that no employee faces any uncertainty, the company has paid salary ahead of schedule, while contractual workers are being given bi-monthly payments to buy essential commodities.
Related Topics:Covid-19 fightDalmia BharatPM Fund
Sonia Gandhi sets up control room on COVID-19
Two youths in Rajasthan made to clean quarantine ward for roaming
Road ahead is a long one, says Modi on COVID-19 fight
'Jammu and Kashmir emerges as good as Kerala in COVID-19 fight'
Free tests may be detrimental to Covid-19 fight, ICMR tells SC
As many as 1,91,181 people were vaccinated on day one of India's first phase of the coronavirus vaccination drive.
Hours after the Health Ministry announced on January 16 that India has reported no case of post-vaccination hospitalisation yet, 51 persons complained of minor adverse events in Delhi. Another person developed severe adverse event following immunization and had to be referred to the AEFI centre.
Out of a total of 4,319 healthcare and frontline workers who were vaccinated on Jnauary 16 in the National Capital, two healthcare workers at NDMC's Charak Palika Hospital reported mild adverse event post-vaccination including mild tightness in the chest. They were kept under observation by AEFI team and discharged 30 minutes later after they felt at ease. The two other cases were reported from Northern Railway Central Hospital, of which one was referred to the AEFI centre, the Delhi government has informed.
Beneficiaries from 11 states and union territories across India received Covishield or Covaxin shots on the first day of the vaccination drive, namely, Assam, Bihar, Delhi, Haryana, Karnataka, Maharashtra, Odisha, Rajasthan, Tamil Nadu, Telangana, and Uttar Pradesh.
Follow our coverage of the coronavirus crisis here
The vaccine maker said in phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19
Hyderabad, January 16: Bharat Biotech, which has received a government purchase order for supply of 55 lakh doses of Covaxin, a COVID-19 vaccine, said the company would pay compensation to recipients in case of any serious adverse effects experienced after receiving the antidote.
In the consent form to be signed by the vaccine recipients, Bharat Biotech said: "In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres/hospitals."
"The compensation for serious adverse event will be paid by sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine," the consent form said.
In phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19. However, the clinical efficacy of the vaccine was yet to be established and it was still being studied in phase 3 clinical trials, the vaccine maker said.
"Hence it is important to appreciate that receiving the vaccine does not mean that other precautions related to COVID-19 need not be followed," the consent form said.
According to an industry expert, the company is liable to pay compensation to people in case of serious side effects as the vaccine is being administered while in the clinical trial mode.
The central licensing authority has granted permission for the sale or distribution of Covaxin for restricted use in emergency situations in public interest as an abundant caution, in clinical trial mode.
Meanwhile, Suchitra Ella, joint managing director, Bharat Biotech International Limited, on her Twitter account said: "Covaxin & Bharat Biotech is truly humbled & honoured to be of service to the nation & the fraternity of all first responders of covid who have served public health." — PTI
Delhi has reported 52 adverse events following events of which one is serious and could involve the guard hospitalised today.
New Delhi, January 16
A 22-year-old security guard at AIIMS, New Delhi reported allergic reaction and is learnt to be in intensive care, moments after the government said there was no post-vaccine hospitalisation.
The 22-year-old guard developed headache, rash, respiratory distress, tachycardia after vaccination. He is in ICU and his condition is stable, hospital sources said.
All beneficiaries vaccinated at AIIMS got indigenous COVAXIN.
Blog8 hours ago